Nationwide Abortion Pill Ban Leaves Millions Without Access Overnight

The Fifth Circuit Court of Appeals has blocked nationwide access to mifepristone via mail and telehealth, requiring the abortion pill to be dispensed in person. This decision is set to reach the Supreme Court.

Ruling Overview

A three-judge panel unanimously sided with Louisiana, which sued the FDA to reverse a rule allowing mifepristone prescriptions through telehealth. Judge Kyle Duncan authored the opinion, joined by Judges Leslie Southwick and Kurt Engelhardt.

Impact on Medication Abortion

Mifepristone, part of a two-drug regime for abortions, makes up a significant portion of U.S. abortions. The ruling disrupts telehealth services that had been used to circumvent state bans post-Dobbs decision.

Arguments and Implications

The court accepted Louisiana's claim of Medicaid expenses from complications as enough for legal standing, despite data showing low risk with mifepristone. The decision raises concerns about increased barriers for those seeking abortions.

Reproductive rights advocates criticize the ruling as politically driven and not based on medical evidence, while emphasizing its impact on women's access to reproductive care, particularly in restricted states.

The case is now progressing to the Supreme Court as issues of legal standing and state costs are debated further, impacting how mifepristone can be accessed across the United States.